PHOENIX Medical Supplies Limited, along with many others in the industry, has expressed its disappointment and frustration over the government’s decision to freeze funding for community pharmacy in England.
On Monday (August 23), the government announced that it would keep funding for the Community Pharmacy Contractual Framework (CPCF) unchanged at £2.592 billion for the year 2021/22, keeping the allocation same for the third consecutive year.
The Pharmaceutical Services Negotiating Committee’s (PSNC) team faced a stiff challenge while negotiating the funding increase demand, and despite “warm words from senior politicians” it met with “a flat rejection” from the Treasury, said Jeremy Meader, managing director at PHOENIX.
He said: “It’s unfathomable that the government has widely acknowledged the importance of community pharmacy in delivering improved health outcomes, yet refuses to recognise this through increased investment.
“The new hypertension service is welcome, yet it is the tip of the iceberg in terms of what pharmacy can offer as a local, valued healthcare hub preventing ill health from arising in the first instance and providing the professional support which those with chronic conditions need.”
Meader added that it is extremely disappointing that the government continues to reject investment in community pharmacy, which countless surveys have shown people want, need and value.
He acknowledged the contractors’ frustrations towards the decision and promised to continue its lobbying efforts.
Meader added that the firm remains committed to support members in maximising their remuneration opportunities.
He added: “We have developed new dispensing, purchasing and digital solutions to support you (members) and help you protect your bottom line whilst improving patient services. Talk to us how we can help you during this time of financial austerity.”